US 11,806,332 B2
Compositions and methods for inhibition of SARS-CoV-2 viral infections
Wenshe Liu, College Station, TX (US); Kai Yang, College Station, TX (US); Erol Vatansever, College Station, TX (US); and Shiqing Xu, College Station, TX (US)
Assigned to THE TEXAS A&M UNIVERSITY SYSTEM, College Station, TX (US)
Filed by THE TEXAS A&M UNIVERSITY SYSTEM, College Station, TX (US)
Filed on May 19, 2022, as Appl. No. 17/748,351.
Application 17/748,351 is a continuation of application No. PCT/US2020/041179, filed on Jul. 8, 2020.
Claims priority of provisional application 63/027,566, filed on May 20, 2020.
Prior Publication US 2022/0273616 A1, Sep. 1, 2022
Int. Cl. A61K 31/40 (2006.01); A61K 31/14 (2006.01); A61P 31/14 (2006.01); A61K 31/4515 (2006.01); A61K 31/454 (2006.01)
CPC A61K 31/40 (2013.01) [A61K 31/454 (2013.01); A61K 31/4515 (2013.01); A61P 31/14 (2018.01)] 7 Claims
OG exemplary drawing
 
1. A method of treating COVID-19 in a patient in need thereof, said method comprising the step of administering a pharmaceutical composition comprising bepridil to the patient, wherein the pharmaceutical composition provides inhibition of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) main protease (MPro).